Outcome in breast molecular subtypes according to nodal status and surgical procedures

Chafika Mazouni, Françoise Rimareix, Marie Christine Mathieu, Catherine Uzan, Céline Bourgier, Fabrice André, Suzette Delaloge, Jean Rémi Garbay

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    45 Citations (Scopus)

    Résumé

    Background: The purpose of our study was to evaluate the surgical treatment and outcome of breast cancer according to molecular subtypes. Methods: We identified 1,194 patients consecutively treated for primary breast cancer from 2004 to 2010. The type of surgery, pathological findings, local recurrence, and distant metastasis were evaluated for 5 molecular subtypes: luminal A and B, luminal HER2 (Human Epidermal Growth Factor Receptor 2), HER2, and triple negative. Results: Breast-conserving surgery (BCS) was performed more frequently in luminal A (70.6%), triple-negative (66.2%), and luminal HER2 tumors (60.9%) (P <.001). A sentinel node biopsy was performed more frequently in luminal A (60%), and luminal HER2 (29.3%) types (P <.001). Among the 791 BCS, positive nodes were observed more often in HER2 (50%) and luminal B (44.9%) types (P = .0003). The number of local recurrences was higher in the node-negative luminal B subtype (3.4%). Conclusions: Molecular subtypes exert an impact on BCS and nodal surgery rates. The local relapse rates are influenced by the molecular subtypes according to the nodal status.

    langue originaleAnglais
    Pages (de - à)662-667
    Nombre de pages6
    journalAmerican Journal of Surgery
    Volume205
    Numéro de publication6
    Les DOIs
    étatPublié - 1 juin 2013

    Contient cette citation